MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Aktien・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Geschlossen

4.49 3.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.35

Max

4.71

Schlüsselkennzahlen
By Trading Economics
Einkommen	4M -3.8M
Verkäufe	522K 1.1M
EPS	-0.014
Gewinnspanne	-357.374
Angestellte	19
EBITDA	75K -7.6M

Dividenden
By Dow Jones
Nächstes Ergebnis	13. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	16M 854M
Vorheriger Eröffnungskurs	1.27
Vorheriger Schlusskurs	4.49

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

3.255 / 3.365 Unterstützung & Widerstand

Arbutus Biopharma Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Apr. 2026, 23:36 UTC

Akquisitionen, Fusionen, Übernahmen

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. Apr. 2026, 23:24 UTC

Heiße Aktien

Stocks to Watch: Gloo, Broadcom, GitLab

14. Apr. 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. Apr. 2026, 21:32 UTC

Wichtige Markttreiber

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. Apr. 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. Apr. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. Apr. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. Apr. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. Apr. 2026, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. Apr. 2026, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. Apr. 2026, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. Apr. 2026, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. Apr. 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

14. Apr. 2026, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. Apr. 2026, 20:32 UTC

Heiße Aktien

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. Apr. 2026, 19:59 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. Apr. 2026, 19:38 UTC

Ergebnisse

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. Apr. 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. Apr. 2026, 19:21 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. Apr. 2026, 19:09 UTC

Akquisitionen, Fusionen, Übernahmen

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. Apr. 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Apr. 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer-Vergleich

Kursveränderung

Arbutus Biopharma Corp Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arbutus Biopharma Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

3.255 / 3.365Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.